Printer Friendly

AFFYMAX RECEIVES AWARD FOR TECHNOLOGY TO SPEED DRUG DISCOVERY

 PALO ALTO, Calif., April 15 /PRNewswire/ -- Affymax (NASDAQ: AFMXF) announced today that the inventors of its VLSIPS(TM)(Very Large Scale Immobilized Polymer Synthesis) technology were awarded the Distinguished Inventor Award by the Intellectual Property Owners Association. Along with Merck & Co. and the Goodyear Tire and Rubber Co., Affymax was recognized for an invention with far-reaching technological and commercial applications. The award was granted to the team of four inventors named on the VLSIPS patent: Stephen P.A. Fodor, Ph.D.; Michael Pirrung, Ph.D.; J. Leighton Read, M.D.; and Lubert Stryer, M.D.
 Affymax's VLSIPS technology is a unique combination of two diverse disciplines -- photolithography and synthetic chemistry -- allowing drug discovery to take place in a miniaturized and automated chip format. Using VLSIPS, Affymax has demonstrated the ability to synthesize and screen thousands of different drug candidates on a tiny "chip" in only a few days. The technology also has powerful applications in the emerging field of genetic analysis.
 "This new technology has the potential to significantly compress the time and cost of drug discovery," stated Alejandro Zaffaroni, chairman and chief executive officer of Affymax. "Enabling technologies such as VLSIPS are the means by which recent discoveries in the field of molecular biology are being transformed into therapies for important human diseases. These powerful new technologies have the potential to offer highly cost-effective treatment of conditions that might previously have required hospitalization."
 The VLSIPS technology was previously recognized by the American Association for the Advancement of Science, which awarded it the Newcomb Cleveland Prize for the best research article published in Science in 1991. The technology was honored for its "interdisciplinary approach, wide potential application and innovative integration of the fields of solid phase chemistry, photolithography and engineering to produce order in chemical synthesis."
 Affymax is developing new technologies to accelerate the pace of drug discovery. Affymax is applying these technologies across a broad range of diseases to discover and develop products independently and in collaboration with established pharmaceutical companies. The majority of the company's research and development activities are performed by its wholly owned subsidiary, Affymax Research Institute, located in Palo Alto.
 -0- 4/15/93
 /CONTACT: Diana E. Kapp of Affymax, 415-496-2300; or Mary Fraker of APCO Associates, 202-778-1038, for Affymax/
 (AFMXF)


CO: Affymax; Affymax Research Institute ST: California IN: MTC SU:

LH-SG -- SJ002 -- 6028 04/15/93 08:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 15, 1993
Words:395
Previous Article:IDB COMMUNICATIONS REPORTS MARCH INCREASES IN INTERNATIONAL LONG DISTANCE MINUTES
Next Article:SANMINA ANNOUNCES INITIAL PUBLIC OFFERING OF 2,300,000 SHARES OF COMMON STOCK
Topics:


Related Articles
AFFYMAX REPORTS THIRD QUARTER RESULTS
AFFYMAX REPORTS FIRST QUARTER RESULTS
AFFYMETRIX APPOINTS TOP MANAGEMENT
AFFYMAX AND ALZA SIGN DEFINITIVE AGREEMENT FOR JOINT DEVELOPMENT PROGRAM
WAHL APPOINTED VICE PRESIDENT OF CLINICAL RESEARCH AT AFFYMAX PHARMACEUTICALS
AFFYMAX TO RECEIVE PROGRESS PAYMENTS FOR TWO COLLABORATIVE AGREEMENTS
AFFYMAX REPORTS THIRD QUARTER RESULTS
Affymax Names Andrew J. Perlman, M.D., Ph.D., Chief Executive Officer.
Affymax Appoints Helen S. Kim Chief Business Officer.
Affymax Appoints Daniel J. Levitt, M.D., Ph.D., as Chief Operating Officer And Head of Research and Development.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters